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hypertension and connective tissue disease.2 3
No definite risk factors were identified in our
patient, except for mild hypertension con-
trolled with drugs.
The pathological hallmark of arterial dissec-
tion is represented by a separation of layers of
the vessel wall usually caused by an intimal
tear that connects the arterial lumen with the
wall of the artery, forming an intramural
haematoma. SAHs are not rare in intracranial
artery dissections because they lack an external
elastic membrane and have a thinner adventi-
tia and fewer elastic fibres in the media as
compared with extracranial vertebral and
carotid arteries.2 3
Diagnosis of intracranial artery dissection
relies on DSA, but MRI and MRA have found a
role in establishing the initial diagnosis and in
the follow-up.1 2 4 DSA signs of arterial dissec-
tions include irregular narrowing (‘‘pearl and
string sign’’), fusiform aneurysm (‘‘pseudoa-
neurysm’’ or dissecting aneurysm) and venous
mural pooling of contrast medium, although
the only pathognomonic DSA finding is the
identification of a double lumen—that is, the
passage of the contrast medium into a true and
false lumen.2 3
MRI is an ideal complement to DSA, as it can
directly enable assessment of the vessel wall
and demonstration of the intramural haema-
toma. The intramural haemotoma typically has
a crescent shape showing hyperintensity to
isointensity in T1-weighted image and hyper-
intensity in proton density and T2-weighted
images in the subacute stage.
The variability of MRI appearance of intra-
mural haematoma reflects differences in the
techniques used (spatial resolution, pulse
sequence) and the time interval between
haemorrhage and examination.4 A combina-
tion of DSA, MRI and MRA findings strongly
supported the diagnosis in our case.
Arterial dissection is a dynamic disease and
this justifies the clinical and neuroradiological
follow-up of patients.4 The healing process at
the site of mural haematoma is responsible for
the change in vessel silhouette with time and
can result in a complete or partial recovery of
the vessel lumen. Sometimes, however, dissec-
tion evolves in vessel occlusion or formation of
pseudo-aneurysm.
The natural history and optimal treatment of
PCA dissecting aneurysms are not established,
but our and other cases1–3 suggest a more
benign outcome as compared with dissections
of the vertebrobasilar arteries. A favourable
outcome was common in patients with ischae-
mia treated conservatively or with anticoagula-
tion. Among nine patients with SAH, four were
treated with surgical or endovascular ‘‘trap-
ping’’ with parent artery occlusion to prevent
re-bleeding and five with a conservative
management.2 3 5 We decided to treat our
patient conservatively because of the poor
clinical conditions at admission and in view
of the rich vascular supply to the brain stem
that originates from P1 segment which makes
occlusion of the parent artery at this level
risky.5
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Early mitoxantrone-induced
cardiotoxicity in secondary
progressive multiple sclerosis
Mitoxantrone is an anthracenedione antineo-
plastic agent approved as an escalating immu-
notherapy for multiple sclerosis. Owing to
structural similarity with other anthracyclines,
cardiotoxicity is a severe side effect of mitox-
antrone. Cardiotoxicity from anthracycline is
considered to be dose dependent and irrever-
sible and to result in the reduction of left
ventricular ejection fraction (LVEF) and con-
gestive heart failure.1 The risk of mitoxantrone-
induced cardiotoxicity in patients with multi-
ple sclerosis increases with cumulative doses
.100 mg/m2 body surface area (BSA).2 3
However, the effect of mitoxantrone on cardiac
function in the early phase of treatment with
cumulative doses ,100 mg/m2 BSA is unclear,
and data on cardiac function regularly mon-
itored from the beginning of treatment are
rare.
From a total number of 18 patients with
secondary progressive multiple sclerosis who
were prospectively assessed at our institution
during the past 2 years, we report on four
patients with a temporary and considerable
decrease in LVEF, and with additional echo-
cardiographic findings of diastolic dysfunction
after only one or two doses of mitoxantrone.
Monitoring of cardiac function and
treatment procedures
All patients receiving mitoxantrone in our
clinic undergo assessment of cardiac function
according to the following protocol: from the
beginning of treatment, transthoracic echocar-
diography is performed every 3 months before
each infusion. Examinations are, whenever
possible (i.e. in about 90% of cases) carried
out by our cardiologists, who perform at least
600 echocardiograms per year. The quantita-
tion of LVEF is based on Simpson’s rule, as
described elsewhere.4 Further, left ventricular
diastolic function is evaluated from the follow-
ing parameters: ratio E (peak early filling
velocity)/A (peak atrial velocity), isovolumetric
relaxation time (IVRT) and E wave decelera-
tion time (DT).5 6 In line with current recom-
mendations,2 patients with an LVEF of ,50%
are excluded from mitoxantrone treatment,
and treatment is discontinued if the LVEF
drops to a value of ,50% or if there are clinical
signs of cardiac dysfunction. If a difference of
.10% is found compared with the preceding
value, the infusion is not applied. After 4–
8 weeks we perform a follow-up echocardio-
graphy and may then continue treatment if the
LVEF has returned to baseline value and our
cardiologists agree to further mitoxantrone
treatment. Unless dose reduction is required
owing to haematological abnormalities, our
patients routinely receive a mitoxantrone dose
of 12 mg/m2 BSA at three-monthly intervals up
to a cumulative dose of 100 mg/m2 BSA, the
maximum approved mitoxantrone dose for
treatment of multiple sclerosis in Germany.
Case reports
All four patients (table 1, fig 1) were scheduled
to receive mitoxantrone according to our
protocol. None of the patients had a history
of cardiac disease, cardiovascular risk factors or
pretreatment with cardiotoxic substances.
Assessment of cardiac status showed no
abnormalities (physical examination, blood
pressure, electrocardiogram, transthoracic
echocardiogram, normal values of serum glu-
cose, cholesterol and triglycerides). Except for
interferon-b treatment, none of the patients
had received any immunomodulatory or
immunosuppressive agents before.
Patient 1 had a pretreatment LVEF of 64%
and the first mitoxantrone dose was well
tolerated. After 3 months, before application
of the second dose, LVEF was found to be 48%
and additional signs of diastolic dysfunction
were detected (prolonged DT and IVRT, E/A
ratio with E,A). Although the patient did not
show clinical signs of cardiac failure, the
second infusion was cancelled in line with
our treatment protocol. Two months later LVEF
was 60%, but diastolic parameters had not
returned to normal values. The patient discon-
tinued mitoxantrone treatment because his
Expanded Disability Status Scale had pro-
gressed to .6, which rules out further use of
mitoxantrone in Germany. A follow-up echo-
cardiogram 10 months later confirmed a nor-
mal LVEF of 60% but persistence of prolonged
DT, suggesting incomplete remission of diasto-
lic dysfunction.
In patient 2, the LVEF before treatment was
66% and the first mitoxantrone dose was well
tolerated. The LVEF after 3 months was 54%,
and so the second infusion was cancelled in
line with our protocol. Prolonged DT indicated
subtle diastolic dysfunction. The patient
showed no clinical signs of cardiac dysfunc-
tion. Although LVEF was 71% and DT had also
returned to normal value after 2 months, the
patient refused continuation of treatment
because she was concerned about the potential
cardiac side effects.
In patient 3, the LVEF before treatment was
65%. Follow-up echocardiogram 3 months
later was normal, and both the first and the
second infusions were well tolerated. Follow-
up echocardiogram before the third scheduled
infusion showed a decrease in LVEF to 52%, as
well as prolonged DT and IVRT; as a result, the
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treatment was temporarily discontinued. The
patient did not have any signs of cardiac
dysfunction. Within several weeks LVEF had
recovered to 63%, but diastolic dysfunction
persisted. After consultation with our cardiol-
ogists we decided to continue mitoxantrone
treatment, and the third and fourth doses have
since been applied. Echocardiogram performed
immediately before the fourth dose showed an
LVEF of 61% with persisting diastolic changes.
So far, no clinical signs of cardiac dysfunction
have been reported by the patient or detected
on physical examination.
Patient 4 had an LVEF of 64% before
treatment, and the first dose was well toler-
ated. The LVEF after 3 months was 55%, with
prolonged DT, but treatment was continued, as
the difference in LVEF was ,10% and the
patient had no clinical signs of cardiac failure.
The second infusion was well tolerated. Before
the third infusion LVEF had decreased to 49%,
with persistent prolongation of DT, but again
without clinical signs of cardiac dysfunction.
Mitoxantrone was discontinued until a control
echocardiogram after several weeks of ramipril
treatment showed a normal LVEF of 64%, and
diastolic parameters also returned to normal
values. The third and fourth doses have since
been applied. LVEF was 60% and diastolic
parameters were normal immediately before
the fourth infusion.
Four other patients had subtle signs of
diastolic dysfunction (prolonged DT, IVRT or
an E/A ratio with E,A) without any detectable
decrease in LVEF and without clinical signs of
cardiac dysfunction after their first or second
mitoxantrone infusion.
Discussion
The therapeutic benefit of mitoxantrone for
patients with worsening multiple sclerosis has
been proved in clinical trials.7 8 Because of rare
but serious cardiotoxicity, its cumulative life-
time dose is limited in patients with multiple
sclerosis. A retrospective analysis of 1378
patients with multiple sclerosis showed an
asymptomatic decrease of LVEF to ,50% in
1.8% of patients below a cumulative dose of
100 mg/m2, compared with 5% above 100 mg/
m2, without continuous monitoring of cardiac
function from the beginning of treatment.3 By
performing regular echocardiography before
each infusion, we detected 4 of 18 prospectively
assessed patients (22%) who transiently
experienced a notable decrease in LVEF of
between 13% and 16% after their first or
second mitoxantrone infusion. All four
patients had additional diastolic changes (pro-
longed DT, IVRT or E/A ratio of E,A), which
remitted in two patients along with normal-
isation of LVEF. Two patients experienced a
drop in LVEF to a value below 50%, which
prohibited continuation of treatment. Four
further patients (another 22%) showed diasto-
lic changes without marked changes in LVEF.
The following points argue against technical
artefacts: (1) primary and follow-up investiga-
tions were performed by the same experienced
echocardiographer in 90% of the examinations,
using the same equipment, and with full access
to prior imaging sequences, allowing compar-
ison of findings with previous results; (2) the
dimension (difference between two measure-
ments .10%) and time frame of changes in
LVEF followed a similar pattern (normal value
at baseline, decrease after the first or second
infusion, and (partial) resolution) in all four
patients; (3) the minor (5% maximum) differ-
ences in LVEF compared with preceding values
in the remaining 14 patients; (4) a coefficient
of variation of 8.6% for variability of LVEF in
our entire group, which is comparable with the
coefficients of variation in a previous study
using Simpson’s rule9; and (5) the quantitation
of LVEF by means of a well-established and
broadly accepted algorithm that has shown
good correlation with cardiac magnetic reso-
nance imaging and better agreement with this
technique than other echocardiographic assess-
ments (ie, Teichholz method).10 11
We provide empirical data for early systolic
and diastolic cardiac dysfunction after the first
or second infusion of mitoxantrone. In line
with a previous report on the rapid-onset
cardiotoxicity of mitoxantrone,12 our findings
indicate that early cardiac dysfunction under
mitoxantrone seems to be more frequent than
so far reported. Taking into account both
systolic and diastolic parameters, we found a
total of 8 of 18 (44%) patients with abnormal
findings on follow-up echocardiograms com-
pared with the pretreatment baseline.
The reasons for early decrease of LVEF
remain unclear. None of our patients had a
history of cardiac disease or had been treated
with cardiotoxic substances before. The dura-
tion of infusion over 60 min makes peak
plasma levels unlikely to cause transient
cardiac dysfunction.13 Our data on early dia-
stolic changes are in line with oncological
studies on anthracycline-induced cardiotoxi-
city, which show that diastolic dysfunction
may occur independently of left ventricular
systolic function or precede disturbances
there.14–16 A recent study which reported no
marked early decrease of LVEF during treat-
ment with mitoxantrone in multiple sclerosis
did not measure functional diastolic para-
meters.17 Histopathological data on anthracy-
cline cardiotoxicity suggest a possible change
in diastolic performance as a result of increased
myocardial stiffness.18 The clinical effect of
early cardiotoxicity is unclear, and to date it is
not known whether early subclinical changes
are a risk factor for symptomatic cardiac
dysfunction later in the course of mitoxantrone
treatment or after its completion.
The increasing evidence for early cardiotoxi-
city calls for regular and frequent cardiac
monitoring from the beginning of mitoxan-
trone treatment. A revision of the product
labelling guidelines for mitoxantrone by the US
Food and Drug Administration in April 2005
(http://www.fda.gov/medwatch/SAFETY/2005/
Novantrone_pl_may24.pdf) recommends that
an echocardiogram or multi-gated radionuclide
angiography be performed before each dose.
The best method for assessment of cardiac
function under mitoxantrone treatment in
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Figure 1 Time course of left ventricular ejection fraction (LVEF) in 18 patients during the early
treatment phase including follow-up LVEF after recovery (*) or withdrawal of treatment (**).
Table 1 Patient characteristics
Patient Sex Age MS course
Disease
duration
(years) EDSS
Pre-treatment
LVEF before
treatment (%)
Dose per
infusion
(mg/m2)
Cumulative
MITOX dose
(mg)
LVEF after
MITOX (%)
Follow-up
LVEF (%)
1 M 37 SPMS 2 6.0 64 12 20.9 48 60
2 F 43 SPMS 6 5.5 66 12 17.7 54 71
3 M 30 SPMS 12 5.5 65 12 46.2 52 63/61
4 M 35 SPMS 3 5.5 64 12 51.4 49 64/60
EDSS, Expanded Disability Status Scale; F, female; LVEF, left ventricular ejection fraction; M, male; MITOX, mitoxantrone; MS, multiple sclerosis; SPMS, secondary
progressive multiple sclerosis.
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patients with multiple sclerosis has not been
evaluated, and there are no longitudinal
studies comparing different techniques (ie,
echocardiography, radionuclide ventriculogra-
phy and magnetic resonance imaging).
Therefore, prospective studies for monitoring
cardiac function in patients with multiple
sclerosis under mitoxantrone are urgently
needed. Appropriate techniques should assess
systolic and diastolic cardiac functions. Any
decisions concerning the discontinuation of
mitoxantrone owing to presumed cardiotoxi-
city should be based on a reliable and accurate
method of assessment, as patients often have
no therapeutic alternative.
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Rasmussen encephalitis with
ipsilateral brain stem involvement
in an adult patient
Rasmussen encephalitis is a rare unihemi-
spheric inflammatory disease of the brain that
leads to intractable seizures, cognitive decline
and progressive neurological deficits associated
with the affected hemisphere. It predominantly
affects children, with the onset in adults
having a milder course. Immunotherapy has
been suggested to improve the outcome of
Rasmussen encephalitis.1 2
Case report
In November 2000, a left-handed 37-year-old
woman experienced a head trauma with brief
loss of consciousness. Shortly after, she had
mild clumsiness of her right leg, which went
on for the next 2 years. No magnetic resonance
imaging (MRI) study was performed at that
time. Her family also noticed a change in her
character (all of which was retrospectively
interpreted as the ‘‘prodromal stage’’ of
Rasmussen encephalitis2).
In February 2002, the patient started having
epilepsia partialis continua (EPC) of her right
hand (later on interpreted as an onset of the
‘‘acute stage’’ of Rasmussen encephalitis2).
Apart from EPC and impaired motor function
of her right leg and hand (due to the EPC), the
neurological examination and electroencepha-
logram were normal at this time. Cerebrospinal
fluid contained 10 cells/ml, had a normal
protein level and showed oligoclonal bands.
Microbiological studies showed no sign of an
infectious agent. MRI of the brain showed a
mild left temporal atrophy. A steroid pulse
treatment was given. However, the motor
deficit progressed, accentuated in the right
hand and leg, with central sensory deficit.
In December 2002, Jacksonian motor sei-
zures of the patient’s right hemibody started
evolving from the EPC. Brain MRI showed left-
sided supratentorial atrophy (most pronounced
around the Sylvian fissure) and increased
fluid-attenuated inversion recovery or T2 signal
of the white matter. The brain stem, however,
was neither atrophic nor did it show an
increased signal (fig 1A, D, G).
In April 2003, the patient presented to our
department (Department of Epileptology,
University of Bonn, Bonn, Germany). MRI
scans showed progression of hemiatrophy of
the left hemisphere and involvement of the left
mesencephalon (fig 1B, E, H). Biopsy speci-
mens of the brain biopsy, obtained from the
left superior frontal gyrus, showed perivascular
and parenchymatous CD3+ CD8+ T lympho-
cytes (partly in close apposition to neurones),
microglial activation and astrogliosis. The
patient received a total of 1.2 g intravenous
immunoglobulins (IvIg) per kilogram body
weight.
On discharge, the patient had a 4/5 right
hemiparesis with hypoesthesia. Further,
monthly courses of 0.4 g IvIg/kg were recom-
mended.3 The patient’s compulsory health
insurance, however, refused to cover the costs
for this kind of treatment. Three months later,
the patient’s hemiparesis had markedly pro-
gressed (arm, 2–3/5; leg, 4/5). Despite reinsti-
tution of monthly IvIg by inpatient treatments
in our department, the patient was hemiplegic
by October 2003 and became seizure free at
about the same time (onset of the ‘‘residual
stage’’2). Fortunately, the patient’s language
abilities were preserved, obviously owing to
atypical dominance (functional MRI scan
disclosed bilateral, predominantly right-sided
activation of frontotemporal regions during
language tasks). IvIg treatment was stopped.
In April 2004, the patient was admitted
because of swallowing and speech problems.
On cranial nerve examination, she had a newly
observed deviation of the uvula to the left side
and reduced soft-palate elevation; gag and
cough reflexes were normal, and speech
showed signs of a flaccid dysarthria. Neither
oculomotor abnormalities nor other signs of
upper brain stem were affected. No cerebellar
signs on the unaffected side were noted. The
MRI scan showed an ongoing progression of
the supratentorial left-sided hemiatrophy and
an increase in signal extending subcortically to
the left mesencephalon and pons, without
contrast enhancement. This strictly unilateral
signal increase in the left pons was newly
observed (fig 1C, F, I). A high-dose long-term
oral steroid treatment was started. One year
later, swallowing and speech problems as well
as the palatal velus paresis had resolved. MRI
was unchanged. The patient is now 41 years
old and remains seizure free.
Discussion
To the best of our knowledge, this is the first
published biopsy-proven case of an adult-onset
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